An integrated overview of the immunosuppression features in the tumor microenvironment of pancreatic cancer
J Guo, S Wang, Q Gao - Frontiers in Immunology, 2023 - frontiersin.org
Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest malignancies. It is
characterized by a complex and immunosuppressive tumor microenvironment (TME), which …
characterized by a complex and immunosuppressive tumor microenvironment (TME), which …
Protein Arginine Methyltransferases in Pancreatic Ductal Adenocarcinoma: New Molecular Targets for Therapy
K Bhandari, WQ Ding - International Journal of Molecular Sciences, 2024 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignant disease with a low 5-year
overall survival rate. It is the third-leading cause of cancer-related deaths in the United …
overall survival rate. It is the third-leading cause of cancer-related deaths in the United …
VPAC2 Receptor Signaling Promotes Growth and Immunosuppression in Pancreatic Cancer
T Passang, S Wang, H Zhang, F Zeng, PC Hsu… - Cancer Research, 2024 - AACR
Pancreatic cancer (PDAC) harbors a complex tumor microenvironment (TME), and crosstalk
between cells in the TME can contribute to drug resistance and relapse. Vasoactive …
between cells in the TME can contribute to drug resistance and relapse. Vasoactive …
[HTML][HTML] The roles of lncRNAs and miRNAs in pancreatic cancer: a focus on cancer development and progression and their roles as potential biomarkers
S Jafari, H Motedayyen, P Javadi, K Jamali… - Frontiers in …, 2024 - frontiersin.org
Pancreatic ductal adenocarcinoma (PDAC) is among the most penetrative malignancies
affecting humans, with mounting incidence prevalence worldwide. This cancer is usually not …
affecting humans, with mounting incidence prevalence worldwide. This cancer is usually not …
Clinical and Preclinical Targeting of Oncogenic Pathways in PDAC: Targeted Therapeutic Approaches for the Deadliest Cancer
DJ Jiménez, A Javed, T Rubio-Tomás… - International Journal of …, 2024 - mdpi.com
Pancreatic ductal adenocarcinoma (PDAC) is one of the leading causes of cancer-related
death worldwide. It is commonly diagnosed in advanced stages and therapeutic …
death worldwide. It is commonly diagnosed in advanced stages and therapeutic …
The Multifaceted Role of miR-21 in Pancreatic Cancers
C Chen, L Demirkhanyan, CS Gondi - Cells, 2024 - mdpi.com
With the lack of specific signs and symptoms, pancreatic ductal adenocarcinoma (PDAC) is
often diagnosed at late metastatic stages, resulting in poor survival outcomes. Among …
often diagnosed at late metastatic stages, resulting in poor survival outcomes. Among …
Exploring the therapeutic potential of focal adhesion kinase inhibition in overcoming chemoresistance in pancreatic ductal adenocarcinoma
F Scianò, F Terrana, C Pecoraro, B Parrino… - Future Medicinal …, 2024 - Taylor & Francis
Pancreatic ductal adenocarcinoma (PDAC) is among the leading causes of cancer-related
deaths worldwide. Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase often …
deaths worldwide. Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase often …
[HTML][HTML] Deoxyribonucleic acid methylation driven aberrations in pancreatic cancer-related pathways
A Bararia, A Das, S Mitra, S Banerjee… - World journal of …, 2023 - ncbi.nlm.nih.gov
Pancreatic cancer (PanCa) presents a catastrophic disease with poor overall survival at
advanced stages, with immediate requirement of new and effective treatment options …
advanced stages, with immediate requirement of new and effective treatment options …
Kikuchi disease: A case report about Sintilimab-induced Kikuchi histiocytic necrotizing lymphadenitis and literature review
C Ren, Y Wang, X Yang, Y Tuo, Y Li, J Gong - Heliyon, 2024 - cell.com
Immune checkpoint inhibitors have become one of the effective means of solid tumor
treatment, among which anti-programmed death-1 (PD-1) antibodies are more maturely …
treatment, among which anti-programmed death-1 (PD-1) antibodies are more maturely …
Efficacy of adding levofloxacin to gemcitabine and nanoparticle-albumin-binding paclitaxel combination therapy in patients with advanced pancreatic cancer: study …
H Imai, Y Sakamoto, S Takahashi, H Shibata, A Sato… - BMC cancer, 2024 - Springer
Background Advanced pancreatic cancer is one of the leading causes of cancer-related
deaths. For patients with advanced pancreatic cancer, gemcitabine and nanoparticle …
deaths. For patients with advanced pancreatic cancer, gemcitabine and nanoparticle …